Contaminated Heparin: Source and Mechanism of Recent Fatal Allergic Responses & Screening Test

ClotCare: Blood Clots, Stroke, Heart Attack

Tuesday, December 3, 2024

Home | DVT/PE | Blood Clots | Coumadin/Warfarin | New Patients | Self Testing | Email List | Donate

Pick a Topic: Home New Postings Patient Postings Clinician Postings Join Our Email List Useful Web Links CE Opportunities Training Programs Guidelines DVT & PE Stories Editorial Board Financial Support About ClotCare DVT Coalition Contact Us Find info on a: Specific Medicine or Treatment Type of Medicine or Treatment Condition or Medical Procedure Lab Test Procedure Management Issue ClotCare complies with the HONcode standard for trustworthy health information: verify here. ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.	Contaminated Heparin: Source and Mechanism of Recent Fatal Allergic Responses & Screening Test Henry I. Bussey, Pharm.D. June, 2008 Reference: Kishimoto TK, Viswanathan K, Ganguly T, et.al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008 Jun 5;358(23):2457-67. Epub 2008 Apr 23. Oversulfated chondroitin sulfate (OSCS), which is somewhat chemically similar to heparin (a sulfated glycosaminoglycan), recently was identified as the contaminant in some batches of heparin that were found to be the source of anaphylactoid allergic reactions and death. In this report, investigators confirm the ability of this substance to activate the body's immunologic system by activating the kinin-kallikrein pathway and components of the complement system that promote anaphylaxis. In addition, the actions appeared to be linked to activation of factor XII as well. The investigators also propose a specific screening test to monitor heparin products for contamination with OSCS or other highly sulfated polysaccharide contaminants that may activate the body's allergic response systems.	Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org. ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters. New Postings: Click here to view full list of new postings
ClotCare Home \| New Postings \| Patient Postings \| Clinician Postings \| Join Our Email List \| Useful Web Links CE Opportunities \| Training Programs \| DVT & PE Stories \| Editorial Board \| Financial Support About ClotCare \| DVT Coalition \| Donate to ClotCare \| Contact Us
Key topics discussed on ClotCare include: Blood Clots \| Deep Vein Thrombosis (DVT) \| Pulmonary Embolism (PE) \| Atrial Fibrillation (A. Fib or AF) \| Heart Attack \| Stroke \| Transient Ischemic Attack (TIA) \| Mini Stroke \| Bleeding Complications \| Vascular Surgery \| Surgical Blood Clot Removal \| Warfarin \| Coumadin \| Lovenox \| Low Molecular Weight Heparin (LMWH) \| Heparin \| Anticoagulants \| Plavix \| Aspirin \| Antiplatelets \| Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved. Terms, Conditions, & Privacy \| Image Copyright Information 19260 Stone Oak Parkway, Suite 101 \| San Antonio, TX 78258 \| 210-860-0487 Send comments to webmaster@clotcare.org. Tuesday, December 3, 2024